ObjectiveEarly recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosi
OS overall survival; ASA American society of anesthesiologists; RFS relapse free survival; UICC International Union Against Cancer.Univariate analysis of prognosis factor for OS and RFS (n = 224).
Sample information of 587 ovarian patients and normal tissue samples with Copy number variation and mRNA data on different platforms. Table S2. Distributions of focal gains/losses in primary tumors an